Key Takeaways Targeted therapy ideal for focal lesions, active edges, and facial/neck sites; enables high local dose while sparing uninvolved […]
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best outcomes on face/neck, slower on acral sites. Typical schedule 2–3×/week for 24–48
Key Takeaways Lesional skin shows elevated H2O2 with reduced antioxidant enzyme activity, notably catalase and glutathione peroxidase. Redox stress perturbs
Key Takeaways IFN-γ → CXCL9/10 → CXCR3+ T cells is the central chemokine axis that sustains melanocyte-directed cytotoxicity. TRM cells
Key Takeaways Topical and oral tofacitinib show signals of repigmentation in case series/open studies, with best facial responses. NB-UVB appears
Key Takeaways Two parallel phase 3 RCTs (TRuE-V1/V2) showed superiority vs vehicle on F-VASI at week 24, with continued gains
Key Takeaways First-line option on trunk/limbs; avoid continuous high-potency use on face, folds, genital skin—prefer calcineurin inhibitors there. Intermittent schedules
Key Takeaways MKTP is a cellular grafting option for clinically stable vitiligo (no new/enlarging lesions for 6–12 months; negative Koebner).
Key Takeaways MKTP is a cellular grafting option for clinically stable vitiligo (no new/enlarging lesions for 6–12 months; negative Koebner).
Key Takeaways Pimecrolimus 1% cream showed superiority to vehicle on facial endpoints (F-VASI) over ~12–24 weeks in split-face and parallel-arm